Eli Lilly Grows Again in Genetic Medicines, Buying Startup With a New Way to Deliver DNA
Engage Bio developed a platform technology that enables non-viral delivery of DNA to cells. The acquisition is the latest in a series of Eli Lilly deals that expand the pharmaceutical company’s pipeline and capabilities in genetic medicines.
MedCity Pivot Podcast: A Conversation About Interoperability with Particle Health’s CEO
Jason Prestinario talks about the state of healthcare interoperability today, while also addressing questions about the interoperability lawsuits he and others are involved in against Epic.
When the Referee Owns the Team — and Tennessee Changes the Rules
At the center of this issue is a simple question: should the entities responsible for managing prescription drug benefits also own the pharmacies that profit from those decisions?
How AI & CMS are Solving the $4 Trillion Healthcare Crisis
The message to the industry is clear: If your business model is optimized only for FFS, you are the legacy. The future of healthcare belongs to those who can trade hours spent for improved patient lives.
Why Patient Engagement Is Clinical Trials’ Next Strategic Frontier
As decentralized trials reduce face time with participants, sponsor organizations that treat engagement as an afterthought will pay for it in dropout rates, missing data and failed endpoints.